Revolutionizing Drug Targeting: Vect-Horus Showcases Cutting-Edge VECTrans® Technology at Viva Technology 2024

A biotechnology company based in Marseille, France, Vect-Horus is renowned for its innovative molecular vectors that facilitate targeted delivery of therapeutic molecules and imaging agents. Recently, the company announced its participation in the Viva Technology conference scheduled to take place in Paris from May 22-25, 2024.

As one of the 10 startups showcasing disruptive technologies at the event, Vect-Horus will present its groundbreaking VECTrans® technology, which revolutionizes drug targeting to the brain and other pathological tissues such as cancer. The company’s Chief Scientific Officer Jean-Manuel Pean will lead a roundtable discussion at the conference to provide an overview of the company’s pipeline, recent advancements in its technology, and progress made in optimizing VECTrans® technology. He will also discuss early clinical trials of theragnostic agents for glioblastoma and pancreatic cancer and updates on partnerships with companies like Novo Nordisk and Ionis Pharmaceuticals.

Founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP), UMR7051, CNRS, and Aix Marseille University, Vect-Horus focuses on developing vectors for targeting and delivering therapeutic and imaging agents to organs and tumors. The company employs 38 individuals primarily in research and development.

For more information about Vect-Horus visit their website at www.vect-horus.com or contact them at contact@vect-horus.com. For media inquiries please reach out to Emmanuelle Bettendorf for BD & Alliance Management at contact@vect-horus.com or Sophie Baumont from Cohesion Bureau for Media Relations at sophie.baumont@cohesionbureau